Results 1 to 10 of about 46,097 (193)
Optimal Controls of the Highly Active Antiretroviral Therapy [PDF]
Abstract and Applied Analysis, 2020 In this paper, we study generic properties of the optimal, in a certain sense, highly active antiretroviral therapy (or HAART). To address this problem, we consider a control model based on the 3-dimensional Nowak–May within-host HIV dynamics model. Taking into consideration that precise forms of functional responses are usually unknown, we introduce ...
Ellina V. Grigorieva +2 more
openaire +3 more sources
Highly active antiretroviral therapy [PDF]
BMJ, 2005 Cardiovascular risk needs to be assessed before starting treatment I n the industrialised world the availability of highly active antiretroviral treatment (HAART) for advanced HIV-1 disease has dramatically improved patients' life expectancy.1 However, an unfailing lifelong commitment to antiviral drugs is expected.
Filip, Moerman +3 more
openaire +4 more sources
Highly Active Antiretroviral Therapy and the Kidney [PDF]
Clinical Journal of the American Society of Nephrology, 2006 Highly active antiretroviral therapy has dramatically altered the treatment and life expectancy of individuals who are infected with HIV. More than 20 antiretroviral drugs and drug combinations now are available in the United States. Nephrologists need to have an understanding of the pharmacokinetics of antiretroviral medications and the proper dosing ...
Jeffrey S, Berns, Nishaminy, Kasbekar
openaire +2 more sources
Evaluation of Adherence to Highly Active Antiretroviral Therapy
Archives of Internal Medicine, 2001 This work has been supported by project 2109/00 from the Fundación para la Investigación y la Prevención del Sida en España (FIPSE), Madrid, Spain.
Martín Fernández, Jesús +3 more
openaire +3 more sources
Highly active antiretroviral therapy [PDF]
Internal Medicine Journal, 2004 The barriers to providing highly active antiretroviral therapy (HAART) in poor countries have until recently seemed insurmountable. The cited problems have ranged from weak health systems and poor infrastructure to inadequate numbers of health professionals. In reality, the main barrier has been the very high cost of antiretroviral drugs.
openaire +2 more sources
Duration of Highly Active Antiretroviral Therapy Regimens [PDF]
Clinical Infectious Diseases, 2003 The median duration of highly active antiretroviral therapy (HAART) regimens was reported to be 11.8 months in one US study, but that study included both treatment-experienced and treatment-naive patients. The duration of initial HAART regimens for treatment-naive patients alone has not been reported.
Ray Y, Chen +9 more
openaire +2 more sources
Highly Active Antiretroviral Therapy (HAART) [PDF]
Journal of Ethiopian Medical Practice, 2001 No Abstract. Journal of Ethiopian Medical Journal Vol. 3(2) 2002: pp.
Daniel Thomas Ginat +1 more
openaire +3 more sources
Nutrition in the Era of Highly Active Antiretroviral Therapy [PDF]
Clinical Infectious Diseases, 2001 Despite tremendous advances in treatment, persons with human immunodeficiency virus (HIV) infection commonly experience a variety of nutritional problems, such as weight loss, fat redistribution, and obesity. We discuss basic dietary and metabolic problems as they pertain to persons with HIV infection and provide practical suggestions for their ...
A H, Shevitz, T A, Knox
openaire +2 more sources
Daily Dosing of Highly Active Antiretroviral Therapy [PDF]
Clinical Infectious Diseases, 2002 Complex treatment schedules for human immunodeficiency virus (HIV) disease, which can have a high pill burden and can include multiple daily doses, in addition to the adverse effects that the medications can cause, may reduce patient adherence to therapy. Reduced adherence prevents achievement of the desired goal of full suppression of HIV replication,
Keith A, Rosenbach +2 more
openaire +2 more sources
Update on highly active antiretroviral therapy: progress and strategies [PDF]
Biomedicine & Pharmacotherapy, 2000 HIV patients who have detectable viral loads (1,000-5,000 copies/mL) and/or evidence of immunologic dysfunction (CD4+ T-lymphocyte count < 500/mm3) should be treated with a potent combination antiretroviral regimen. Currently, this is to consist of two nucleoside reverse transcriptase inhibitors (NRTIs) with at least one protease inhibitor (PI), or a ...
Clumeck, Nathan, De Wit, Stéphane
openaire +2 more sources